Form 4 for QNCX Quince Therapeutics, Inc.
Accepted 2022-03-04 00:00:00 ET · period of report 2022-03-03 · accession 0001209191-22-016440 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-04 | 2022-03-03 | QNCX | LOWE CHRISTOPHER P. | COO, CFO, Interim CEO | A - Grant | $0.00 | +175.0K | 265.0K | +194% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-03 | A | A | 175,000 | $0.00 | 265,000 | D | — | — | (F1) Represents grant of Restricted Stock Units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant. |